A collection of essays examining the current status of the therapeutic potential of hallucinogenic substances, exploring how the drugs can be used to effectively treat a wide range of conditions.

Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca • Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker. Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago by the U.S. government as well as offering non-technical summaries of the most recent studies with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health. Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field, the growing threat of overmedication by the pharmaceutical industry, and the links between psychiatric drugs and mental illness. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.

This handbook reviews promising applications of psychedelics in treatment of such challenging psychiatric problems as posttraumatic stress disorder, major depression, substance use disorders, and end-of-life anxiety. Experts from multiple disciplines synthesize current knowledge on psilocybin, MDMA, ketamine, and other medical hallucinogens. The volume comprehensively examines these substances' neurobiological mechanisms, clinical effects, therapeutic potential, risks, and anthropological and historical contexts. Coverage ranges from basic science to practical clinical considerations, including patient screening and selection, dosages and routes of administration, how psychedelic-assisted sessions are structured and conducted, and management of adverse reactions.

This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

This reference places the latest information at users' fingertips, and a more streamlined format makes it easy to find the exact information quickly and conveniently. Includes access to a companion Web site for additional resources.

Neuropathology of Drug Addictions and Substance Misuse, Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects is the second of three volumes in this informative series and offers a comprehensive examination of the adverse consequences of the most common drugs of abuse. Each volume serves to update the reader’s knowledge on the broader field of addiction as well as to deepen understanding of specific addictive substances. Volume 2 addresses stimulants, club and dissociative drugs, hallucinogens, and inhalants and solvents. Each section provides data on the general, molecular and cellular, and structural and functional neurological aspects of a given substance, with a focus on the adverse consequences of addictions. Research shows that the neuropathological features of one addiction are often applicable to those of others, and understanding these commonalties provides a platform for studying specific addictions in more depth and may ultimately lead researchers toward new modes of understanding, causation, prevention, and treatment. However, marshalling data on the complex relationships between addictions is difficult due to the myriad material and substances. Offers a modern approach to understanding the pathology of substances of abuse, offering an evidence-based ethos for understanding the neurology of addictions Fills an existing gap in the literature by serving as a “one-stop-shopping synopsis of everything to do with the neuropathology of drugs of addiction and substance misuse Includes in each chapter: list of abbreviations, abstract, introduction, applications to other addictions and substance misuse, mini-dictionary of terms, summary points, 6+ figures and tables, and full references Offers coverage of preclinical, clinical, and population studies, from the cell to whole organs, and from the genome to whole body

Edited by two preeminent scholars, this book provides coverage of the policy issues related to the increasingly diverse treatments, practices, and applications of psychedelics. Hallucinogenic substances like LSD, mescaline, peyote, MDMA, and ayahuasca have a reputation as harmful substances that are enjoyed only by recreational users committing criminal acts. But leading international researchers and scholars who contributed to this book hold that the use of psychedelic substances for health, religious, intellectual, and artistic purposes is a Constitutional right—and a human right. Based on that conclusion, these scholars focus on policy issues that regulate the use of psychedelic drugs in medicine, religion, personal life, and higher education, arguing that existing regulations should match current and anticipated future uses. This volume has two parts. The first surveys research on the use of psychedelic drugs in medicine, religion, and truth-seeking, following these topics through history and contemporary practice. The second section treats government policices that regulate the psychological, physiological, biochemical, and spiritual aspects of research and experience in these fields. The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society challenges medical and legal policy experts, ethicists, scientists, and scholars with the question: How can we formulate policies that reduce the dangers of psychedelics' misuse and at the same time maximize the emerging diverse benefits?